Betting on early-stage biotech companies is rarely for the faint of heart. Regulatory uncertainty, clinical trial risks, and funding concerns often make these stocks among the market’s most volatile. Yet this year, one of the riskiest biotech companies, AtaiBeckley (ATAI), which makes psychedelic-based mental health therapies, delivered a standout payoff for investors who were willing to take that risk.
Atai stock has soared 213% year-to-date (YTD), wildly outperforming the S&P 500 Index’s ($SPX) gain of 17.9%. Is ATAI still a buy for 2026?
